Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Gilead Sciences, Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Gilead Sciences, Inc.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Gilead Sciences, Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's enterprise value to sales, at 6.61 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Rating Financials

Gilead Sciences, Inc. SectorMexico

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Gilead Sciences, Inc. SectorMexico

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Gilead Sciences, Inc. SectorMexico

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Gilead Sciences, Inc. SectorMexico

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Gilead Sciences, Inc. SectorMexico

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
186B
AA
1,028B
A
651B -
BBB
- -
466B
AAA
-
346B
AA
266B
AAA
259B
A
208B
A
191B
BBB
186B
AA
Average 378.79B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. GILD Stock
  4. GILD * Stock
  5. Ratings Gilead Sciences, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!